Clinical trial
Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers
NCT03112733 is registered in ClinicalTrials.gov with Ilker Kahramanoglu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers
- Lead sponsor
- Ilker Kahramanoglu
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- April 4, 2017
- Completion date
- May 30, 2019
- Enrollment
- 171 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.